Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study

It has been hypothesized that low levels of C1 esterase inhibitor (C1-INH), a key inhibitor of the complement pathway, may play a role in the occurrence of adverse events (AEs) associated with intravenous immunoglobulin (IVIG) therapy. This open-label pilot study evaluated C1-INH replacement, with r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Immunol
Asıl Yazarlar: Melamed, Isaac R., Miranda, Holly, Heffron, Melinda, Harper, Joseph R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Immunology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7962274/
https://ncbi.nlm.nih.gov/pubmed/33737935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.632744
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller